These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 9765336

  • 1. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [Abstract] [Full Text] [Related]

  • 2. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 3. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
    Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G.
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
    [Abstract] [Full Text] [Related]

  • 4. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A.
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [Abstract] [Full Text] [Related]

  • 5. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [Abstract] [Full Text] [Related]

  • 6. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
    Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, Mcallister G, Myers J, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S, Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ, Ragan CI.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):636-47. PubMed ID: 9353380
    [Abstract] [Full Text] [Related]

  • 7. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, Leeson PD, Patel S, Ragan CI, Ridgill M, Saywell KL, Tricklebank MD.
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [Abstract] [Full Text] [Related]

  • 8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, Peglion JL.
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [Abstract] [Full Text] [Related]

  • 9. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Adhumeau A, Brocco M, Nicolas JP, Boutin JA, Despaux N, Peglion JL.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [Abstract] [Full Text] [Related]

  • 10. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 11. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [Abstract] [Full Text] [Related]

  • 12. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S.
    J Pharmacol Exp Ther; 1995 Nov; 275(2):885-98. PubMed ID: 7473180
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ, Svenningsson P, Ashby CR, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A.
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [Abstract] [Full Text] [Related]

  • 15. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.
    J Med Chem; 2005 Feb 10; 48(3):839-48. PubMed ID: 15689168
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K, Lutzke BS, Mccall RB, Piercey MF, Schreur PJ, Sethy VH, Smith MW, Svensson KA, Tang AH, Vonvoigtlander PF, Tenbrink RE.
    J Pharmacol Exp Ther; 1996 Dec 10; 279(3):1392-403. PubMed ID: 8968364
    [Abstract] [Full Text] [Related]

  • 17. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A.
    Eur J Pharmacol; 2006 Mar 27; 535(1-3):135-44. PubMed ID: 16554049
    [Abstract] [Full Text] [Related]

  • 18. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, Rivet JM, Sicard D, Billiras R, Brocco M.
    J Pharmacol Exp Ther; 2008 Mar 27; 324(3):1212-26. PubMed ID: 18096759
    [Abstract] [Full Text] [Related]

  • 19. Novel (R)-2-amino-5-fluorotetralins: dopaminergic antagonists and inverse agonists.
    Malmberg A, Höök BB, Johansson AM, Hacksell U.
    J Med Chem; 1996 Oct 25; 39(22):4421-9. PubMed ID: 8893836
    [Abstract] [Full Text] [Related]

  • 20. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
    Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, Terranova MA, Donnelly-Roberts DL, Namovic MT, Miller TR, Wetter JM, Marsh K, Stewart AO, Brioni JD, Moreland RB.
    Neuropharmacology; 2005 Jul 25; 49(1):112-21. PubMed ID: 15992586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.